Phase II study of M118103

Phase II study of M118103 in the treatment of nodular prurigo which does not respond to topical steroid treatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223825

Enrollment

Registered

2018-02-27

Start date

2018-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nodular prurigo which does not respond to topical steroid treatment

Interventions

investigational material(s) Generic name etc : M118103 INN of investigational material : Heparinoid Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational materia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with nodular prurigo which does not respond to topical steroid treatment patients

Exclusion criteria

Exclusion criteria: 1) Patients who have a history or presence of serious drug hyper sensivity 2) Patients who have cardiac, hepatic, renal, pulmonary, blood disease considered inappropriate for participation in clinical trials

Design outcomes

Primary

Measure	Time frame
efficacy exploratory IGA, pruritus The investigator will assess IGA at every visit and patients will assess NRS every day.	—

Secondary

Measure	Time frame
safety NA NA	—

Countries

Japan

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026